Effects of Cigarette Smoking and Cytochrome P450 2D6 Genotype on Fluvoxamine Concentration in Plasma of Japanese Patients
スポンサーリンク
概要
- 論文の詳細を見る
Fluvoxamine is a selective serotonin reuptake inhibitor widely used in the treatment of depression and other psychiatric diseases. The aim of this study was to assess the clinical impact of cigarette smoking on plasma fluvoxamine concentration in Japanese patients, and evaluate whether the cytochrome P450 (CYP) 1A2 and CYP2D6 genotypes have effects on that concentration. Thirty-two Japanese patients receiving fluvoxamine were enrolled. They were maintained on the same daily dose of fluvoxamine (mean±S.D., 109.4±66.2 mg/d) for at least 4 weeks to obtain the steady-state plasma concentration. The steady-state plasma concentration-to-dose (C/D) ratio of fluvoxamine in patients who smoked (n=6, 11.8±6.5 ng/ml/dose) was significantly lower than that in non-smoker patients (n=26, 22.8±11.2 ng/ml/dose). There was no significant difference for the C/D ratio of fluvoxamine in patients with CYP1A2 −3860G/G, −3860G/A, and −3860A/A between non-smokers and smokers. Among non-smoker patients, the C/D ratios of fluvoxamine in those with one and two mutated alleles of CYP2D6 were 1.6- and 1.4-fold higher, respectively, than those with no mutated alleles, though the differences among those three genotype groups were not significant. Furthermore, stepwise multiple regression analysis revealed that cigarette smoking and daily dose had significant positive correlations with the plasma concentration of fluvoxamine. Our findings suggest that cigarette smoking has a significant impact on the steady-state plasma concentration of fluvoxamine in Japanese patients.
- 日本薬学会の論文
著者
-
KAGAWA Yoshiyuki
Department of Pharmacy, Mie University Hospital, Faculty of Medicine, Mie University
-
KAWAKAMI Junichi
Department of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine, University of Tokyo
-
YAMADA Shizuo
Department of Pharmacokinetics and Pharmacodynamics and Global Center of Excellence (COE) Program, S
-
UCHIDA Shinya
Department of Pharmacokinetics and Pharmacodynamics and Global COE Program, School of Pharmaceutical
-
Uchida Shinya
Department Of Pharmacokinetics And Pharmacodynamics School Of Pharmaceutical Sciences University Of
-
Uchida Shinya
Department Of Biopharmacy School Of Pharmaceutical Sciences University Of Shizuoka
-
NAMIKI Noriyuki
Department of Pharmacy, The Jikei University School of Medicine Daisan Hospital
-
Namiki Noriyuki
Department Of Earth And Planetary Sciences Kyushu University
-
MORI Norio
Department of Psychiatry, Hamamatsu University School of Medicine
-
KAWAI Masayoshi
Department of Psychiatry and Neurology, Hamamatsu University School of Medicine
-
Kagawa Yoshiyuki
Department Of Clinical Pharmaceutics And Pharmacy Practice Faculty Of Pharmaceutical Sciences Univer
-
Katoh Yasuhiro
Department of Pharmacy Practice and Science, School of Pharmaceutical Sciences, University of Shizuo
-
Takei Noriyoshi
Department of Psychiatry, Hamamatsu University School of Medicine
-
Hashimoto Hisakuni
Nihon Pharmaceutical University
-
Yamada Shizuo
Department Of Biophamacy School Of Pharmaceutical Sciences University Of Shizuoka
-
Katoh Yasuhiro
Department Of Orthopaedic Surgery Nagoya City University Medical School
-
Mori Norio
Department Of Neuropsychiatry Fukushima Medical College
-
Kawakami Junichi
Department Of Hospital Pharmacy Hamamatsu University School Of Medicine
-
Katoh Yasuhiro
Departments Of Pharmacy Practice & Science School Of Pharmaceutical Sciences University Of Shizu
-
Kawai Masayoshi
Department Of Mechanical Engineering Ibaraki University
-
Uchida Shinya
Department Of Anesthesiology Gunma University Hospital
-
Yamada Shizuo
Department of Pharmacokinetics & Pharmacodynamics, School of Pharmaceutical Sciences, University of Shizuoka
-
Uchida Shinya
Department of Pharmacy Practice and Science, University of Shizuoka
-
Katoh Yasuhiro
Department of Pharmacy Practice and Science, University of Shizuoka
-
Kagawa Yoshiyuki
Department of Clinical Pharmaceutics & Pharmacy Practice, Graduate School of Pharmaceutical Sciences, University of Shizuoka
-
Namiki Noriyuki
Department of Pharmacy Practice and Science, University of Shizuoka
-
Namiki Noriyuki
Department of Clinical Pharmacology & Therapeutics, Hamamatsu University School of Medicine
関連論文
- The Forefront for Novel Therapeutic Agents Based on the Pathophysiology of Lower Urinary Tract Dysfunction: Bladder Selectivity Based on In Vivo Drug–Receptor Binding Characteristics of Antimuscarinic Agents for Treatment of Overactive Bladder
- Pharmacologically Relevant Receptor Binding Characteristics and 5α-Reductase Inhibitory Activity of Free Fatty Acids Contained in Saw Palmetto Extract(Pharmacology)
- Effects of Dietary Ingredients on Function and Expression of P-Glycoprotein in Human Intestinal Epithelial Cells
- The Impact of Total Bilirubin on Plasma Micafungin Levels in Living-Donor Liver Transplantation Recipients with Severe Liver Dysfunction(Biopharmacy)
- INHIBITION OF GABA_A RECEPTOR-MEDIATED CURRENT RESPONSES BY ENOXACIN (NEW QUINOLONE) AND FELBINAC (NON-STEROIDAL ANTI-INFLAMMATORY DRUG) IN XENOPUS OOCYTES INJECTED WITH MOUSE-BRAIN MESSENGER RNA
- Structure-Activity Relationships of Receptor Binding of 1,4-Dihydropyridine Derivatives(Pharmacology)
- Inhibitory Effect of Azole Antifungal Agents on the Glucuronidation of Lorazepam Using Rabbit Liver Microsomes in Vitro
- PJ-566 Influence of CYP2C9 Genotype on Pharmacokinetics and Pharmacodynamics of Benzbromarone(Cardiovascular pharmacology, basic/clinical-6, The 71st Annual Scientific Meeting of the Japanese Circulation Society)
- OJ-002 Influence of Genetic Polymorphisms of OATP-C on Cholesterol Lowering Effect of Pravastatin(Cardiovascular pharmacology, basic/clinical-2 (H) OJ1,Oral Presentation (Japanese),The 70th Anniversary Annual Scientific Meeting of the Japanese Circulation
- OE-271 Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolaemia and hypertension(Cardiovascular Pharmacology, Basic/Clinical 1 (H) : OE34)(Oral Presentation (English))